1.
The insights on post-marketing evaluation in China;
关于我国药品上市后评价技术工作的思考
2.
Post-marketing Reevaluation and Risk Control Measures of Acarbose
阿卡波糖的上市后评价与风险控制研究
3.
Study on Assessing Value of Public Company after Share Trading Reform;
股权分置改革后上市公司价值评估研究
4.
Re-evaluation of Post-marketing Safety for LevamisoleⅢ:Risk Prevention Countermeasures;
左旋咪唑上市后安全性再评价Ⅲ：风险预防对策
5.
Post-prject Evaluation of Line M8 Changing Project of Shanghai Mass Transmit
上海市轨道交通M8线牵降变工程项目后评价
6.
Comparison of Quality Evaluation System of Post-marketing Drug in China,USA and Japan
中日美药品上市后质量评价体系的比较
7.
Detective and Evaluation of Safety Signals to the Post-marketing Chinese Herbal Drugs
中成药上市后“安全性信号”的识别与评价
8.
Postmarketing Review of Astemizole Safety Assessment in Cardiovascular System
阿司咪唑上市后心脏毒性安全性评价文献调研
9.
An Introduction to Methods for Economic Evaluation of Marketed Medicines I: Setting up an Economic Framework and Reviewing Existing Evidence;
上市后药物经济学评价方法(Ⅰ)——建立经济学评价框架,评价经济学证据(英文)
10.
Post-market Reevaluation of the Effectiveness and Safety of Double-Coptis-Powder Injection in the Treatment of Children's Acute upper Respiratory Infection
双黄连粉针剂治疗儿童急性上呼吸道感染的上市后再评价研究
11.
Post-marketing Surveillance and Evaluation of Contraceptives among Rural Women in Jangsu Province;
在江苏省农村妇女中进行的避孕药具上市后监测与评价
12.
Study on the Supervision and Re-evaluation Approach to Post-market Medical Products of FDA;
FDA对医药产品上市后监测与再评价的方法及其启示
13.
Study on Post-evaluation Model of Listed Companies Introducing International Strategic Investors;
上市公司引进国际战略投资者的后评价模型研究
14.
Methods for Economic Evaluation of Marketed Medicines Ⅱ: Conducting Primary Economic Evaluation;
上市后药物经济学评价方法Ⅱ:药物经济学原始研究
15.
Evidence-Based Safety Reassessment of Post Marketed Drug - Importance of Recall of Refecoxib;
应重视上市后药物安全性的循证医学再评价——罗非昔布召回的意义
16.
Systematic Review of Literature on Post-marketing Safety Evaluation of Quinolone Drugs
喹诺酮类药品上市后安全性评价文献的系统性分析
17.
Safety of Astemizole in Non-cardiovascular System:Analysis of Literature
阿司咪唑上市后非心脏毒性安全性评价文献分析
18.
Safety re-evaluation on nimesulide in treatment of rheumatoid arthritis and osteoarthritis after postmarketing
尼美舒利治疗类风湿关节炎和骨关节炎上市后安全性再评价